Overview

An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).

Status:
Completed

Trial end date:
2019-07-25

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in participants with OAB for up to 52 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Urovant Sciences GmbH

Treatments:

Tolterodine Tartrate